-
The Indianapolis-based pharmaceutical company, Eli Lilly and Company, announced Wednesday it will lower the prices of its branded insulin by 70 percent and will introduce more price caps for its non-branded insulin.
-
T1International, an advocacy group for type 1 diabetics, is calling on pharmaceutical companies like Eli Lilly to lower their insulin prices. The group has been pushing these efforts in Indianapolis for several years.
-
The U.S. Equal Employment Opportunity Commission alleges Lilly’s managers changed practices to hire more young employees, including requiring “higher levels of review and approval” for older applicants, through at least 2021. The commission says managers knew these practices “constituted unlawful age discrimination,” but continued them anyway.
-
In many ways, pregnant people, hospitals, and OB-GYNs will immediately experience the effects of Indiana's new abortion restrictions. The timeline for economic repercussions is less clear after the law goes into effect Sept. 15.
-
The price of insulin has more than tripled in the past two decades; A one-month supply of Eli Lilly’s Humalog has jumped from $21 in 1996 to about $275 in 2019.
-
Eli Lilly also joined other large employers, including Kroger and Amazon, in pledging to cover travel for reproductive services unavailable locally.
-
Eli Lilly announced Friday it will put $500,000 of seed money toward a new network focused on community public health research in Indiana aimed at increasing diversity in clinical trials.
-
The pharmaceutical company Eli Lilly announced a $2 billion expansion in Indiana during a press conference at the Governor’s mansion on Wednesday.
-
Indianapolis-based pharmaceutical giant Eli Lilly last week said it was shifting its business focus in Russia, but all 167 employees there remain employed.
-
The Michigan attorney general’s office has launched an investigation into what it calls excessive insulin prices, specifically targeting Eli Lilly, one of the largest drug companies in the U.S.